These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 25546215

  • 1. Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients.
    Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M.
    Clin Nucl Med; 2015 Feb; 40(2):111-5. PubMed ID: 25546215
    [Abstract] [Full Text] [Related]

  • 2. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T, Kowalska A, Lesiak J, Młynarczyk J.
    Nucl Med Rev Cent East Eur; 2014 Feb; 17(2):87-93. PubMed ID: 25088108
    [Abstract] [Full Text] [Related]

  • 3. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
    Sabet A, Binse I, Grafe H, Ezziddin S, Görges R, Poeppel TD, Bockisch A, Rosenbaum-Krumme SJ.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
    [Abstract] [Full Text] [Related]

  • 4. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S.
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [Abstract] [Full Text] [Related]

  • 5. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, Tanabe H, Fukukura Y, Nakabeppu Y, Koriyama C.
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A.
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, Chung SK.
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [Abstract] [Full Text] [Related]

  • 8. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E, Aras G, Kucuk NO.
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [Abstract] [Full Text] [Related]

  • 9. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K, Pipatrattana R, Tepmongkol S, Sirisalipoch S, Chaiwatanarat T.
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [Abstract] [Full Text] [Related]

  • 10. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
    Ranade R, Kand P, Basu S.
    Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
    [Abstract] [Full Text] [Related]

  • 11. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 12. The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer.
    Alzahrani AS, Abouzied ME, Salam SA, Mohamed G, Rifai A, Al Sugair A, Amin T.
    Eur J Endocrinol; 2008 May; 158(5):683-9. PubMed ID: 18426827
    [Abstract] [Full Text] [Related]

  • 13. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
    Weber T, Ohlhauser D, Hillenbrand A, Henne-Bruns D, Reske SN, Luster M.
    Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
    [Abstract] [Full Text] [Related]

  • 14. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [Abstract] [Full Text] [Related]

  • 15. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S, Aksoy SY, Vatankulu B, Aliyev A, Uslu L, Ozhan M, Sager S, Halac M, Sonmezoglu K.
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [Abstract] [Full Text] [Related]

  • 16. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan.
    Kunawudhi A, Pak-art R, Keelawat S, Tepmongkol S.
    Clin Nucl Med; 2012 Jun; 37(6):561-7. PubMed ID: 22614187
    [Abstract] [Full Text] [Related]

  • 17. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
    Rizzo A, Perotti G, Zagaria L, Lanni V, Racca M, Palestini N, Salvatori M.
    Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of (18)F-FDG PET/CT metabolic parameters in metastatic differentiated thyroid cancers.
    Masson-Deshayes S, Schvartz C, Dalban C, Guendouzen S, Pochart JM, Dalac A, Fieffe S, Bruna-Muraille C, Dabakuyo-Yonli TS, Papathanassiou D.
    Clin Nucl Med; 2015 Jun; 40(6):469-75. PubMed ID: 25899591
    [Abstract] [Full Text] [Related]

  • 19. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F, Alongi P, Evangelista L, Picchio M, Saladini G, Rensi M, Geatti O, Castello A, Laghai I, Popescu CE, Dolci C, Crivellaro C, Seghezzi S, Kirienko M, De Biasi V, Cocciolillo F, Quartuccio N, Young AIMN Working Group.
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [Abstract] [Full Text] [Related]

  • 20. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K, Hay JH, Wilson DC.
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.